About DRG Epidemiology
DRG’s Epidemiology provides bottom-up, patient-level forecasts, detailing disease trends from 10- to 20-year outlook periods to help you validate investments and identify growth opportunities in your markets of interest.
All of our epidemiological data, methods and insight are distributed via DRG’s Insights Platform, allowing the user to easily navigate between world regions and patient populations, as well as download epidemiological forecast data into an MS Excel format for offline use.
All epidemiological forecasts may be supplemented with custom deliverables, such as:
- Chart reviews or more granular stratification using DRG’s in-house real world datasets or physician survey data
- Customized and interactive patient flow models or additional subpopulations or metrics
- Expanded geographical coverage or extended forecast periods beyond those available
Our robust patient population sizing data includes therapeutic coverage of 140+ indications and 3400+ patient subpopulations, including extensive oncology subpopulation data by stage, line of therapy, and biomarker, as well as continually expanding niche and rare disease coverage.
The geographic breadth of data includes mature market (G7) reporting for all 140+ indications, as well as 90% global population coverage for the high-profile diseases, and expanded penetration for emerging and rest-of-world markets in select indications.
For over 20 years, our data and methodology have been developed and refined by DRG’s Epidemiology team of industry-leading subject matter experts, driven by rigorous methodology to uncover the impact of exposure, risk, and treatment, in addition to historical trends and age and gender cohorts.
All of our epidemiological forecasts are accompanied by a transparent description of our methods and data sources, the details of our systematic review underlying each forecast and associated summary evidence tables, and access to the authoring epidemiologist.
- Mature Markets Data
- Key Findings
- Diagnosed Incidence of Human Immunodeficiency Virus Infection Among People of All Ages in 2018 and 2028
- Relative Sizes of the Contributing Factors to the Trend in Diagnosed Incident Cases of Human Immunodeficiency Virus Infection Over the Next Ten Years
- Number of Diagnosed Incident Cases of Human Immunodeficiency Virus Infection Avoided Over the Period from 2018 to 2028 in the Countries Under Study as a Result of PrEP Program Implementation
- Prevalence of Human Immunodeficiency Virus Infection Among People of All Ages in 2018 and 2028
- Relative Sizes of the Factors Contributing to the Prevalence of Human Immunodeficiency Virus Infection Over the Next Ten Years
- Number of Total Prevalent Cases of Human Immunodeficiency Virus Infection Incurred Over the Period from 2018 to 2028 as a Result of Improved Survival
- Epidemiology Data
- Diagnosed Incidence
- Total Prevalence
- Diagnosed Prevalence
- Diagnosed and Drug-Treated Prevalence
- PrEP-Eligible Population
- Reference Materials
- Literature Review
- Risk/Protective Factors
Author(s): Sunali D. Goonesekera, SM
Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group. Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.